- Home
- FERA vs BWAY Comparison
FERA vs BWAY Comparison
Compare FERA & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FERA
- BWAY
- Stock Information
- Founded
- FERA 2024
- BWAY 2003
- Country
- FERA Cayman Islands
- BWAY Israel
- Employees
- FERA N/A
- BWAY N/A
- Industry
- FERA
- BWAY Medical/Dental Instruments
- Sector
- FERA
- BWAY Health Care
- Exchange
- FERA Nasdaq
- BWAY Nasdaq
- Market Cap
- FERA 317.7M
- BWAY 280.7M
- IPO Year
- FERA 2025
- BWAY 2019
- Fundamental
- Price
- FERA $10.16
- BWAY $15.77
- Analyst Decision
- FERA
- BWAY Strong Buy
- Analyst Count
- FERA 0
- BWAY 2
- Target Price
- FERA N/A
- BWAY $18.00
- AVG Volume (30 Days)
- FERA 9.3K
- BWAY 79.0K
- Earning Date
- FERA 01-01-0001
- BWAY 11-11-2025
- Dividend Yield
- FERA N/A
- BWAY N/A
- EPS Growth
- FERA N/A
- BWAY 515.14
- EPS
- FERA N/A
- BWAY 0.11
- Revenue
- FERA N/A
- BWAY $46,084,000.00
- Revenue This Year
- FERA N/A
- BWAY $339.49
- Revenue Next Year
- FERA N/A
- BWAY $21.74
- P/E Ratio
- FERA N/A
- BWAY $55.77
- Revenue Growth
- FERA N/A
- BWAY 26.50
- 52 Week Low
- FERA $9.87
- BWAY $7.70
- 52 Week High
- FERA $10.20
- BWAY $16.25
- Technical
- Relative Strength Index (RSI)
- FERA N/A
- BWAY 67.06
- Support Level
- FERA N/A
- BWAY $15.32
- Resistance Level
- FERA N/A
- BWAY $16.25
- Average True Range (ATR)
- FERA 0.00
- BWAY 0.59
- MACD
- FERA 0.00
- BWAY -0.07
- Stochastic Oscillator
- FERA 0.00
- BWAY 70.25
About FERA Fifth Era Acquisition Corp I Class A Ordinary Shares
Fifth Era Acquisition Corp I is a blank check company.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.